Loading…
← CockpitCompetitor Analysis › 300006.SZ Chongqing Lummy Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Chongqing Lummy Pharmaceutical Co., Ltd. Class A300006.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum leader 99
Mkt cap
$1.21B
US dollars, full cap
Free float
84%
of shares outstanding
$/day
$338M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-12.1 pp
WACC 6.2%
Hurdle
+57 pp
Req g minus delivered
Close · CNYCN¥7.97
1D-15.8%
1W-32.9%
1M+2.8%
3M+48.4%
6M+25.9%
YTD+55.1%
1Y+70.7%
ATR %14.8%
52w lowhigh37.1% off high

What Chongqing Lummy Pharmaceutical does

Employees: 1,115

Chongqing Lummy Pharmaceutical at a glance

Size Chongqing Lummy Pharmaceutical (300006.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.21B, the 1842nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.97 on 18 Nov 2026.

Performance Over six months the shares gained 25.9%, against -20.6% for the median peer and -20.0% for the China market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue fell 6.2% over the last twelve months (peer median +7.6%); the operating margin is -18.6% (peer median 0.8%).

Valuation It trades at 10.4× enterprise value to sales against a peer median of 7.6× (8th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 44% a year for seven years (Req g). Recent delivered growth is -13%, so the hurdle is +57 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 12.1 points below its cost of capital (6.2% WACC).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026300006.SZ 133Peer median 81
Six months, rebased to 100: Chongqing Lummy Pharmaceutical against the median of its 20 peers (local-currency closes).

Chongqing Lummy Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥720MCN¥769MCN¥785MCN¥883MCN¥874M
Revenue growth—-2%-11%+1%—
Gross profitCN¥394MCN¥389MCN¥466MCN¥569MCN¥593M
EBITDAn/a-CN¥47.7M-CN¥66.9M-CN¥32.8M-CN¥72.5M
Net income-CN¥119M-CN¥135M-CN¥87.8M-CN¥8.93M-CN¥68.7M
Free cash flowCN¥40.4MCN¥23.2MCN¥146M-CN¥46.9MCN¥50.0M
Capital expenditureCN¥30.6MCN¥38.2MCN¥75.5MCN¥59.3MCN¥68.2M
Total debtCN¥358MCN¥379MCN¥495MCN¥274MCN¥365M

Quarterly statements and history in the cockpit →

Chongqing Lummy Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%2616HROW2493347850IDIA300026688321688443AVLNNKTR6855GPCR000950000989GHRSAMPH4547002332300006.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Chongqing Lummy Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%+200%0×250×500×750×2616HROW2493347850300026688443NKTR6855300204300006.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Chongqing Lummy Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%300026000989688076AMPH002332300006.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Chongqing Lummy Pharmaceutical is the large dot.

Chongqing Lummy Pharmaceutical competitors and peer comparison

How Chongqing Lummy Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Chongqing Lummy Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure300006.SZPeer medianRank in peer set
1-month return+2.8%-5.4%6th highest of 21
6-month return+25.9%-20.6%2nd highest of 21
Distance from 52-week high-37.1%-41.7%10th highest of 21
Revenue growth (TTM)-6.2%+7.6%5th lowest of 18
Operating margin-18.6%0.8%9th lowest of 18
EV / Sales10.4×7.6×8th most expensive of 18
Growth the price implies (Req g, 7 yrs)44.1%2.5%most demanding of 6
Growth delivered (Del g)-13.2%-1.3%lowest of 6
Hurdle (Req g minus delivered)+57.3 pp+1.0 ppmost demanding of 6
ROIC minus cost of capital-12.1 pp-5.1 pp8th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Chongqing Lummy Pharmaceutical 300006.SZChina$1.21B+26%-6%-19%10.4×44.1%-13.2%
CStone Pharmaceuticals 2616.HKHong Kong$1.21B-22%+117%-89%17.0×n/an/a
Harrow HROWUnited States$1.21B+4%+21%1%4.7×n/an/a
Mabwell (Shanghai) Bioscience 2493.HKHong Kong$1.20B-29%+21%-127%13.6×n/an/a
D&D Pharmatech 347850.KSSouth Korea$1.22B-49%-77%-2,324%818.8×n/an/a
Idorsia IDIA.SWSwitzerland$1.22B-9%-5%-70%10.4×n/an/a
Tianjin Chase Sun Pharmaceutical 300026.SZChina$1.23B-10%-29%3%1.8×7.0%-5.3%
Shenzhen Chipscreen Biosciences 688321.SSChina$1.18B-38%+27%12%7.6×n/an/a
Chongqing Genrix Biopharmaceutical 688443.SSChina$1.18B-22%+256%-27%8.6×n/an/a
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a
Nektar Therapeutics NKTRUnited States$1.18B-50%-17%-304%13.3×n/an/a
Ascentage Pharma Group International 6855.HKHong Kong$1.18B-34%+70%-220%13.2×n/an/a
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%0.5×n/an/a
Jiuzhitang 000989.SZChina$1.16B-7%+46%19%2.6×-4.0%-9.0%
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%4.8×3.4%+27.9%
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%39.1×n/an/a
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%2.3×2.5%+15.5%
Kissei Pharmaceutical 4547.TJapan$1.14B+3%+6%6%1.4×n/an/a
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%2.0×-0.4%-1.3%

Questions

Which companies are Chongqing Lummy Pharmaceutical's closest peers?
The cockpit's peer set: CStone Pharmaceuticals (2616.HK), Harrow (HROW), Mabwell (Shanghai) Bioscience (2493.HK), D&D Pharmatech (347850.KS), Idorsia (IDIA.SW), Tianjin Chase Sun Pharmaceutical (300026.SZ), Shenzhen Chipscreen Biosciences (688321.SS), Chongqing Genrix Biopharmaceutical (688443.SS).
Is Chongqing Lummy Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 10.4× against a peer median of 7.6×, 8th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 44% a year for seven years (Req g). Recent delivered growth is -13%, so the hurdle is +57 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Chongqing Lummy Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned +25.9% against -20.6% for the median peer; over one year +70.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.